Samah Abdel Baki, MD

Chief Executive Officer

Samah Abdel Baki, MD

Dr Baki is the Chief Executive Officer as well as the Chief Medical Officer at BSG. He holds advanced degrees in medicine and economics and leads an active NIH-funded clinical research program. He has lead the clinical research that established the technological and clinical rationales for incorporating the wireless microEEG® platform into the work up of patients presenting with neurological emergencies. This foundation is established by over 20 papers in the peer-reviewed primary clinical literature. Dr. Baki leads NIH-funded clinical trials that utilize pediatric neurologists at State University of New York/ Downstate Medical Center (SUNY-DMC) to interpret microEEGs recorded from patients in multiple New York area neonatal intensive care units. The work is refining the rationale and technical platform to continuously and conveniently monitor preterm infants at risk of life-threatening events. His research has focused on establishing a multi-drug regimen to treat the cognitive deficits that ensue following mild and severe forms of traumatic brain injury (TBI). With colleagues at SUNY-DMC, he was able to discover a drug pair that was unusually potent in treating cognitive deficits after TBI. The US Army honored this research by recognizing it as one of the most outstanding research projects funded by the Congressionally Directed Medical Research Programs (CDMRP) in fiscal year 2007. Dr. Baki and the BSG team are especially proud that the microEEG® platform is being used to identify clinically undetected seizures, guide treatment, and reduce neurological damage and mortality of pediatric patients suffering from cerebral malaria in Malawi, Africa.